西格列汀治疗2型糖尿病的疗效及对患者空腹血糖和糖化血红蛋白水平的影响

Efficacy of sitagliptin in the treatment of type 2 diabetes mellitus and its influence on fasting blood glucose and glycosylated hemoglobin levels

目的探究西格列汀治疗2型糖尿病的疗效及对患者空腹血糖(FBG)和糖化血红蛋白(HbA_(l)c)水平的影响。方法选取2020年1月至2021年6月本院收治的80例2型糖尿病患者作为研究对象,按照随机数字表法分为对照组与观察组,各40例。对照组接受胰岛素治疗,观察组接受西格列汀联合胰岛素治疗,比较两组胰岛功能指标、血糖指标、不良反应发生情况。结果治疗前,两组空腹血糖(FBG)、餐后2 h血糖(2 h PG)、HbA_(l)c水平比较差异无统计学意义;治疗后,两组FBG、2 h PG、HbA_(l)c水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗前,两组稳态模型评估-胰岛素功能指数(HOMA-β)、稳态模型评估-胰岛素抵抗指数(HOMA-IR)、空腹胰岛素(FINS)水平比较差异无统计学意义;治疗后,两组FINS水平、HOMA-IR均低于治疗前,HOMA-β均高于治疗前,且观察组FINS水平、HOMA-IR均低于对照组,HOMA-β高于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论西格列汀联合胰岛素治疗2型糖尿病患者疗效显著,可稳定控制患者血糖,改善胰岛功能,提高患者预后效果,且安全性较高,值得临床推广应用。

Objective To explore the efficacy of sitagliptin in the treatment of type 2 diabetes mellitus and its influence on the levels of fasting blood glucose(FBG)and glycosylated hemoglobin(HbA_(l)c).Methods 80 patients with type 2 diabetes admitted to our hospital from January 2020 to June 2021 were selected as the research subject,and they were divided into the control group and the observation group according to the random number table method,with 40 cases in each group.The control group received insulin therapy,and the observation group received sitagliptin combined with insulin therapy,the islet function index,blood sugar index and adverse reactions were compared between the two groups.Results Before treatment,there was no significant difference in fasting blood glucose(FBG),postprandial blood glucose(2 h PG)and glycosylated hemoglobin(HbA_(l)c)between the two groups;after treatment,the levels of FBG,2 h PG and HbA_(l)c in the two groups were lower than those before treatment,and the observation group were lower than the control group,the differences were statistically significant(P<0.05).Before treatment,there were no significant differences in the levels of homeostasis model assessment of insulin secretion index(HOMA-β),homeostasis model assessment of insulin resistance index(HOMA-IR)and fasting insulin(FINS)between the two groups;after treatment,FINS level and HOMA-IR in two groups were lower than before treatment,HOMA-βwas higher than before treatment,and FINS level and HOMA-IR in the observation group were lower than those in the control group,and HOMA-βwas higher than that in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion The efficacy of sitagliptin combined with insulin in the treatment of patients with type 2 diabetes mellitus is remarkable,which can stably control blood sugar,improve islet function and improve the prognosis of patients,and it is safe and worthy of clinical promotion and application.